PDG20 Cost-effectiveness of Nivolumab in Patients with Pre-treated Advanced Renal Cell Carcinoma (aRCC) in the United States: Impact of >5 Years of Follow-up Data from Checkmate 025
| Autor: | May, J., Malcolm, B., Ejzykowicz, F., Kurt, M., Borrill, J., Theriou, C., Teitsson, S. |
|---|---|
| Zdroj: | In Value in Health December 2020 23 Supplement 2:S524-S524 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect